Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS.

Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25. Erratum in: Neurology. 2018 Sep 11;91(11):538.

2.

Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies.

VanMeter SA, Kavanagh ST, Warren S, Barrett RW.

CNS Drugs. 2012 Sep 1;26(9):773-80. doi: 10.2165/11634870-000000000-00000.

PMID:
22849331
3.

Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.

Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG.

J Clin Psychiatry. 2006 Jun;67(6):865-73.

PMID:
16848645

Supplemental Content

Loading ...
Support Center